Compare ALCO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | SENS |
|---|---|---|
| Founded | 1960 | 1996 |
| Country | United States | United States |
| Employees | 172 | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.9M | 213.2M |
| IPO Year | 1994 | 2014 |
| Metric | ALCO | SENS |
|---|---|---|
| Price | $39.86 | $5.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $44.00 | $18.38 |
| AVG Volume (30 Days) | 14.9K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $39.76 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $29.50 | $0.41 |
| 52 Week High | $45.01 | $8.75 |
| Indicator | ALCO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 45.77 |
| Support Level | $39.98 | $5.26 |
| Resistance Level | $41.96 | $8.55 |
| Average True Range (ATR) | 1.10 | 0.48 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 8.51 | 36.46 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.